ImmunityBio’s Stock Update
ImmunityBio (NASDAQ: IBRX) closed on Monday at $9.83, marking a 12.99% increase. This jump follows impressive financial results where its revenue surged by 700% and losses narrowed. Investors are now keenly observing upcoming approvals and global partnerships, which may impact continued demand. Trading volume reached 85.8 million shares, significantly above the three-month average of 31.1 million. Since going public in 2015, ImmunityBio’s stock has decreased by 72%.
The S&P 500 reported a decrease of 1.01%, with 6,840 cases noted. Meanwhile, the Nasdaq Composite dipped 1.13%, ending at 22,627. In the biotech sector, companies like Ivans Biotherapeutics closed at $2.89, up 0.70%, while Crystal Biotech ended at $274.59, reflecting ongoing strength among drug developers.
Sales of ImmunityBio’s primary product, Anctiva, saw a remarkable 700% growth in 2025 and a sequential rise of 20% in the fourth quarter. Anctiva is currently approved for certain bladder cancer treatments in the U.S., EU, UK, Saudi Arabia, and 33 other countries, with international launches ramping up.
Recently, Anctiva received approval in Saudi Arabia for treating specific lung cancers, hinting at a potential expansion of its application. ImmunityBio is also focused on enhancing its pipeline, ramping up clinical trial participation in areas such as glioblastoma, sepsis, non-Hodgkin lymphoma, and lymphopenia cases. However, with the stock having already surged fivefold in the past, investors should approach early-stage biotech stocks with caution moving into 2026.
Before considering an investment in ImmunityBio, it might be wise to note that the Motley Fool Stock Advisor suggests a list of ten stocks viewed as potential better investment opportunities right now, leaving ImmunityBio off that list. These alternatives are anticipated to yield strong returns over the next few years.
For instance, if you’d invested $1,000 in Netflix when it was first recommended back in December 2004, it could be worth approximately $424,262 today. Similarly, a $1,000 investment in Nvidia from April 2005 would be valued at around $1,163,635 now.
It’s also worth mentioning that the Stock Advisor has a total average return of 904%, compared to the S&P 500’s 194%, indicating a noteworthy market outperformance. Don’t overlook the opportunity to engage with an investing community comprised of retail investors.
